Cytokine regulation of the epidermal barrier

Clinical and Experimental Allergy

Volumn 43, Issue 6, 2013, Pages 586-598

  Gutowska Owsiak, D ^a   Ogg, G S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 3; BETA DEFENSIN 3; CALPAIN 1; CATHEPSIN D; CLAUDIN 3; CYTOKINE; FILAGGRIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; INTERLEUKIN 25; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 6; INVOLUCRIN; LORICRIN; MESSENGER RNA; PROFILAGGRIN; PROTEIN S 100; RETINOIC ACID; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG; UVOMORULIN;

ANTIMICROBIAL ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL JUNCTION; CELL MIGRATION; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; EPIDERMIS BARRIER; FOOD ALLERGY; HUMAN; KERATINOCYTE; LAMELLAR BODY; LIPID COMPOSITION; LIPOGENESIS; PERMEABILITY BARRIER; PH; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; STRATUM CORNEUM; TIGHT JUNCTION; TISSUE REGENERATION; TURNOVER TIME; UPREGULATION; WATER RETENTION;

ANIMALS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CYTOKINES; EPIDERMIS; HUMANS; INFLAMMATION; INTERCELLULAR JUNCTIONS; INTERMEDIATE FILAMENT PROTEINS; KERATINOCYTES; LIPID METABOLISM; PEPTIDE HYDROLASES; SIGNAL TRANSDUCTION; SKIN; WATER;

EID: 84878358608     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12023     Document Type: Review

References (165)

1. Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WH, Shimizu H. Clinical severity correlates with impaired barrier in filaggrin-related eczema. J Invest Dermatol 2009; 129:682-9.
2. Beck LA, Leung DY. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000; 106:S258-63.
3. Gutowska-Owsiak D, Ogg GS. The epidermis as an adjuvant. J Invest Dermatol 2012; 132:940-8.
4. Gomes PL, Malavige GN, Fernando N et al. Characteristics of Staphylococcus aureus colonization in patients with atopic dermatitis in Sri Lanka. Clin Exp Dermatol 2011; 36:195-200.
5. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001; 108:269-74.
6. Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992; 165:1064-8.
7. Ricci G, Patrizi A, Neri I, Bendandi B, Masi M. Frequency and Clinical Role of Staphylococcus aureus Overinfection in Atopic Dermatitis in Children. Pediatr Dermatol 2003; 20:389-92.
8. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51:785-98.
9. Beck LA, Boguniewicz M, Hata T et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124:260-9 e261-7.
10. Wollenberg A, Wetzel S, Burgdorf WHC, Haas J. Viral infections in atopic dermatitis: Pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112:667-74.
11. Gao PS, Rafaels NM, Hand T et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009; 124:507-13 e501-7.
12. McPherson T, Sherman VJ, Aslam A et al. Filaggrin null mutations associate with increased frequencies of allergen-specific CD4+ Th2 cells in patients with atopic eczema. Br J Dermatol 2010; 163:544-9.
13. McPherson T, Aslam A, Crack L, Chan H, Jones L, Ogg G. Frequencies of circulating allergen-specific T cells temporally associate with longitudinal changes in severity of cutaneous atopic disease. Clin Exp Dermatol 2010; 35:786-8.
14. Fallon PG, Sasaki T, Sandilands A et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009; 41:602-8.
15. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995; 96:302-18.
16. Leung DYM. Preface to atopic dermatitis intervention to control the atopic march. J Allergy Clin immunol 2003; 112:S117.
17. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:S118-27.
18. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009; 339:b2433.
19. Weidinger S, Illig T, Baurecht H et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118:214-9.
20. Novak N, Baurecht H, Schafer T et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008; 128:1430-5.
21. Brown SJ, Asai Y, Cordell HJ et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011; 127:661-7.
22. Aslam A, Lloyd-Lavery A, Warrell DA, Misbah S, Ogg GS. Common filaggrin null alleles are not associated with hymenoptera venom allergy in Europeans. Int Arch Allergy Immunol 2011; 154:353-5.
23. Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med 1999; 31:5-19.
24. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-6.
25. De Benedetto A, Rafaels NM, McGirt LY et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127:773-86 e777.
26. Sybert VP, Dale BA, Holbrook KA. Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol 1985; 84:191-4.
27. Furuse M, Hata M, Furuse K et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002; 156:1099-111.
28. Presland RB, Boggess D, Lewis SP, Hull C, Fleckman P, Sundberg JP. Loss of normal profilaggrin and filaggrin in flaky tail (ft/ft) mice: an animal model for the filaggrin-deficient skin disease ichthyosis vulgaris. J Invest Dermatol 2000; 115:1072-81.
29. Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70.
30. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12:21-7.
31. Albanesi C. Keratinocytes in allergic skin diseases. Curr Opin Allergy Clin Immunol 2010; 10:452-6.
32. Sandilands A, O'Regan GM, Liao H et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 2006; 126:1770-5.
33. Enomoto H, Hirata K, Otsuka K et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: a family and case-control study. J Hum Genet 2008; 53:615-21.
34. Zhang H, Guo Y, Wang W, Shi M, Chen X, Yao Z. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis. Allergy 2011; 66:420-7.
35. Flohr C, England K, Radulovic S et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010; 163:1333-6.
36. Akiyama M. FLG mutations in ichthyosis vulgaris and atopic eczema: spectrum of mutations and population genetics. Br J Dermatol 2010; 162:472-7.
37. Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol 2009; 129:543-52.
38. Nomura T, Akiyama M, Sandilands A et al. Prevalent and rare mutations in the gene encoding filaggrin in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Invest Dermatol 2009; 129:1302-5.
39. Cai SC, Chen H, Koh WP et al. Filaggrin Mutations are Associated with Recurrent Skin Infection in Singaporean Chinese Patients with Atopic Dermatitis. Br J Dermatol 2012; 166:200-3.
40. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126:332-7.
41. Howell MD, Fairchild HR, Kim BE et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 2008; 128:2248-58.
42. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120:150-5.
43. Sehra S, Yao Y, Howell MD et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 2010; 184:3186-90.
44. Hvid M, Johansen C, Deleuran B, Kemp K, Deleuran M, Vestergaard C. Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines - a possible link between reduced skin barrier function and inflammation? Exp Dermatol 2011; 20:633-6.
45. Noh M, Yeo H, Ko J, Kim HK, Lee CH. MAP17 is associated with the T-helper cell cytokine-induced down-regulation of filaggrin transcription in human keratinocytes. Exp Dermatol 2010; 19:355-62.
46. Nickoloff BJ, Mitra RS, Elder JT, Fisher GJ, Voorhees JJ. Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br J Dermatol 1989; 121:161-74.
47. Nickoloff BJ, Mahrle G, Morhenn V. Ultrastructural effects of recombinant gamma-interferon on cultured human keratinocytes. Ultrastruct Pathol 1986; 10:17-21.
48. Huffmeier U, Traupe H, Oji V et al. Loss-of-function variants of the filaggrin gene are not major susceptibility factors for psoriasis vulgaris or psoriatic arthritis in German patients. J Invest Dermatol 2007; 127:1367-70.
49. Junghans V, Gutgesell C, Jung T, Neumann C. Epidermal cytokines IL-1beta, TNF-alpha, and IL-12 in patients with atopic dermatitis: response to application of house dust mite antigens. J Invest Dermatol 1998; 111:1184-8.
50. Kim BE, Howell MD, Guttman E et al. TNF-alpha Downregulates Filaggrin and Loricrin through c-Jun N-terminal Kinase: Role for TNF-alpha Antagonists to Improve Skin Barrier. J Invest Dermatol 2011; 131:1272-9.
51. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207-11.
52. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008; 181:7420-7.
53. Eyerich K, Pennino D, Scarponi C et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009; 123:59-66 e54.
54. Toda M, Leung DY, Molet S et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111:875-81.
55. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128:2625-30.
56. Gutowska-Owsiak D, Schaupp AL, Salimi M et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012; 21:104-10.
57. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol 2011; 131:150-7.
58. Eyerich S, Eyerich K, Pennino D et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119:3573-85.
59. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-autoreactive T cells are a normal component of the human alphabeta T cell repertoire. Nat Immunol 2010; 11:1102-9.
60. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174:3695-702.
61. Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol 2011; 165:492-8.
62. Wolk K, Witte E, Wallace E et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36:1309-23.
63. Cornelissen C, Marquardt Y, Czaja K et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012; 129:426-33, 433 e1-8.
64. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005; 516:180-1.
65. Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006; 117:418-25.
66. Dahler AL, Cavanagh LL, Saunders NA. Suppression of Keratinocyte Growth and Differentiation by Transforming Growth Factor [beta]1 Involves Multiple Signaling Pathways. J Invest Dermatol 2001; 116:266-74.
67. Matsumoto K, Hashimoto K, Hashiro M, Yoshimasa H, Yoshikawa K. Modulation of growth and differentiation in normal human keratinocytes by transforming growth factor-beta. J Cell Physiol 1990; 145:95-101.
68. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther 2004; 17(Suppl. 1):43-8.
69. Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol 2010; 126:1184-90 e1183.
70. Horii I, Kawasaki K, Koyama J et al. Histidine-rich protein as a possible origin of free amino acids of stratum corneum. Curr Probl Dermatol 1983; 11:301-15.
71. Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules: Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta 1982; 719:110-7.
72. O'Regan GM, Kemperman PMJH, Sandilands A et al. Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes. J Allergy Clin Immunol 2010; 126:574-80 e571.
73. Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD. Natural moisturizing factor components in the stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive methods. Br J Dermatol 2009; 161:1098-104.
74. Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ. In Vivo Confocal Raman Microspectroscopy of the Skin: Noninvasive Determination of Molecular Concentration Profiles. J Invest Dermatol 2001; 116:434-42.
75. González FJ, Alda J, Moreno-Cruz B et al. Use of Raman spectroscopy for the early detection of filaggrin-related atopic dermatitis. Skin Res Technol 2011; 17:45-50.
76. Kamata Y, Yamamoto M, Kawakami F et al. Bleomycin Hydrolase Is Regulated Biphasically in a Differentiation- and Cytokine-dependent Manner. J Biol Chem 2011; 286:8204-12.
77. Hara M, Verkman AS. Glycerol replacement corrects defective skin hydration, elasticity, and barrier function in aquaporin-3-deficient mice. Proc Natl Acad Sci USA 2003; 100:7360-5.
78. Nakagawa N, Sakai S, Matsumoto M et al. Relationship between NMF (lactate and potassium) content and the physical properties of the stratum corneum in healthy subjects. J Invest Dermatol 2004; 122:755-63.
79. Hara M, Ma T, Verkman AS. Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery. J Biol Chem 2002; 277:46616-21.
80. Ma T, Hara M, Sougrat R, Verbavatz JM, Verkman AS. Impaired stratum corneum hydration in mice lacking epidermal water channel aquaporin-3. J Biol Chem 2002; 277:17147-53.
81. Nakahigashi K, Kabashima K, Ikoma A, Verkman AS, Miyachi Y, Hara-Chikuma M. Upregulation of aquaporin-3 is involved in keratinocyte proliferation and epidermal hyperplasia. J Invest Dermatol 2011; 131:865-73.
82. Yamamoto A, Serizawa S, Ito M, Sato Y. Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res 1991; 283:219-23.
83. Imokawa G. Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol 2001; 45:S29-32.
84. Higuchi K, Hara J, Okamoto R, Kawashima M, Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000; 350(Pt 3):747-56.
85. Imokawa G. A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. J Dermatol Sci 2009; 55:1-9.
86. Man MQ, Wood L, Elias PM, Feingold KR. Cutaneous barrier repair and pathophysiology following barrier disruption in IL-1 and TNF type I receptor deficient mice. Exp Dermatol 1999; 8:261-6.
87. Barland CO, Zettersten E, Brown BS, Ye J, Elias PM, Ghadially R. Imiquimod-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged murine epidermis. J Invest Dermatol 2004; 122:330-6.
88. Jung YJ, Jung M, Kim M, Hong SP, Choi EH. IL-1alpha stimulation restores epidermal permeability and antimicrobial barriers compromised by topical tacrolimus. J Invest Dermatol 2011; 131:698-705.
89. Jensen JM, Schutze S, Forl M, Kronke M, Proksch E. Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. J Clin Invest 1999; 104:1761-70.
90. Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol 2005; 124:786-92.
91. Hatano Y, Katagiri K, Arakawa S, Fujiwara S. Interleukin-4 depresses levels of transcripts for acid-sphingomyelinase and glucocerebrosidase and the amount of ceramide in acetone-wounded epidermis, as demonstrated in a living skin equivalent. J Dermatol Sci 2007; 47:45-7.
92. Wang XP, Schunck M, Kallen KJ et al. The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol 2004; 123:124-31.
93. Caubet C, Jonca N, Brattsand M et al. Degradation of Corneodesmosome Proteins by Two Serine Proteases of the Kallikrein Family, SCTE//KLK5//hK5 and SCCE//KLK7//hK7. J Invest Dermatol 2004; 122:1235-44.
94. Schechter NM, Choi EJ, Wang ZM et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 2005; 386:1173-84.
95. Magert HJ, Standker L, Kreutzmann P et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999; 274:21499-502.
96. Deraison C, Bonnart C, Lopez F et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007; 18:3607-19.
97. Komatsu N, Takata M, Otsuki N et al. Elevated Stratum Corneum Hydrolytic Activity in Netherton Syndrome Suggests an Inhibitory Regulation of Desquamation by SPINK5-Derived Peptides. J Invest Dermatol 2002; 118:436-43.
98. Hachem J-P, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH Directly Regulates Epidermal Permeability Barrier Homeostasis, and Stratum Corneum Integrity/Cohesion. J Invest Dermatol 2003; 121:345-53.
99. Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz) 2009; 57:345-54.
100. Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005; 125:183-200.
101. Kato T, Takai T, Mitsuishi K, Okumura K, Ogawa H. Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1: Biochemical skin barrier against mite cysteine proteases. J Allergy Clin Immunol 2005; 116:169-76.
102. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol 2009; 161:70-7.
103. Komatsu N, Saijoh K, Kuk C et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol 2007; 16:513-9.
104. Han Y-P, Hughes MW, Nien Y-D, Garner WL. IL-8-Stimulated Expression of Urokinase-Type Plasminogen Activator in Human Skin and Human Epidermal Cells. J Surg Res 2002; 106:328-34.
105. Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J. TNF-α and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res 2000; 292:180-7.
106. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143:728-32.
107. Yano S, Banno T, Walsh R, Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008; 214:1-13.
108. Bando M, Hiroshima Y, Kataoka M et al. Interleukin-1alpha regulates antimicrobial peptide expression in human keratinocytes. Immunol Cell Biol 2007; 85:532-7.
109. Tohyama M, Hanakawa Y, Shirakata Y et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009; 39:2779-88.
110. Sa SM, Valdez PA, Wu J et al. The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis. J Immunol 2007; 178:2229-40.
111. Walsh SV, Hopkins AM, Nusrat A. Modulation of tight junction structure and function by cytokines. Adv Drug Deliv Rev 2000; 41:303-13.
112. Feldmeyer L, Huber M, Fellmann F, Beckmann JS, Frenk E, Hohl D. Confirmation of the origin of NISCH syndrome. Hum Mutat 2006; 27:408-10.
113. Wan H, Winton HL, Soeller C et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999; 104:123-33.
114. Winton HL, Wan H, Cannell MB et al. Cell lines of pulmonary and non-pulmonary origin as tools to study the effects of house dust mite proteinases on the regulation of epithelial permeability. Clin Exp Allergy 1998; 28:1273-85.
115. Wan H, Winton HL, Soeller C et al. Quantitative structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house dust mite allergen Der p 1. Clin Exp Allergy 2000; 30:685-98.
116. Kirschner N, Bohner C, Rachow S, Brandner JM. Tight junctions: is there a role in dermatology? Arch Dermatol Res 2010; 302:483-93.
117. Haftek M, Hansen MU, Kaiser HW, Kreysel HW, Schmitt D. Interkeratinocyte adherens junctions: immunocytochemical visualization of cell-cell junctional structures, distinct from desmosomes, in human epidermis. J Invest Dermatol 1996; 106:498-504.
118. Kobayashi J, Inai T, Morita K et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine 2004; 28:186-9.
119. Fujii-Maeda S, Kajiwara K, Ikizawa K et al. Reciprocal Regulation of Thymus and Activation-Regulated Chemokine//Macrophage-Derived Chemokine Production by Interleukin (IL)-4//IL-13 and Interferon-[gamma] in HaCaT Keratinocytes Is Mediated by Alternations in E-cadherin Distribution. J Investig Dermatol 2004; 122:20-8.
120. Capaldo CT, Nusrat A. Cytokine regulation of tight junctions. Biochim Biophys Acta 2009; 1788:864-71.
121. Watson RE, Poddar R, Walker JM et al. Altered claudin expression is a feature of chronic plaque psoriasis. J Pathol 2007; 212:450-8.
122. Rozlomiy VL, Markov AG. Effect of interleukin-1beta on the expression of tight junction proteins in the culture of HaCaT keratinocytes. Bull Exp Biol Med 2010; 149:280-3.
123. Kirschner N, Poetzl C, von den Driesch P et al. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am J Pathol 2009; 175:1095-106.
124. Niemann HH, Schubert WD, Heinz DW. Adhesins and invasins of pathogenic bacteria: a structural view. Microbes Infect 2004; 6:101-12.
125. Montes LF. Systemic abnormalities and the intracellular site of infections of the stratum corneum. JAMA 1970; 213:1469-72.
126. Niyonsaba F, Ogawa H. Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents β-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 2005; 40:157-68.
127. Howell MD, Boguniewicz M, Pastore S et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006; 121:332-8.
128. Howell MD, Novak N, Bieber T et al. Interleukin-10 Downregulates Anti-Microbial Peptide Expression in Atopic Dermatitis. J Invest Dermatol 2005; 125:738-45.
129. Nograles KE, Suarez-Farinas M, Shemer A et al. Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. J Allergy Clin Immunol 2010; 125:744-6 e741-2.
130. Albanesi C, Fairchild HR, Madonna S et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179:984-92.
131. Pernet I, Reymermier C, Guezennec A et al. Calcium triggers beta-defensin (hBD-2 and hBD-3) and chemokine macrophage inflammatory protein-3 alpha (MIP-3alpha/CCL20) expression in monolayers of activated human keratinocytes. Exp Dermatol 2003; 12:755-60.
132. Liu AY, Destoumieux D, Wong AV et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 2002; 118:275-81.
133. Bando M, Hiroshima Y, Kataoka M et al. Modulation of calprotectin in human keratinocytes by keratinocyte growth factor and interleukin-1alpha. Immunol Cell Biol 2010; 88:328-33.
134. Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011; 131:329-37.
135. Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schroder J-M. Differential Gene Induction of Human [beta]-Defensins (hBD-1, -2, -3, and -4) in Keratinocytes Is Inhibited by Retinoic Acid. J Invest Dermatol 2004; 123:522-9.
136. Erdag G, Morgan JR. Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg 2002; 235:113-24.
137. Liang SC, Tan XY, Luxenberg DP et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271-9.
138. Peric M, Koglin S, Kim SM et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008; 181:8504-12.
139. Eyerich S, Wagener J, Wenzel V et al. IL-22 and TNF-alpha represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol 2011; 41:1894-901.
140. Harder J, Schröder J-M. RNase 7, a Novel Innate Immune Defense Antimicrobial Protein of Healthy Human Skin. J Biol Chem 2002; 277:46779-84.
141. Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol 2012; 132:1326-9.
142. Liu YJ. Thymic stromal lymphopoietin: Master switch for allergic inflammation. J Exp Med 2006; 203:269-73.
143. Yoo J, Omori M, Gyarmati D et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. Exp Med 2005; 202:541-9.
144. Gilliet M, Soumelis V, Watanabe N et al. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J Exp Med 2003; 197:1059-63.
145. Li M, Messaddeq N, Teletin M, Pasquali JL, Metzger D, Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Nat Acad Sci 2005; 102:14795-800.
146. Ebner S, Nguyen VA, Forstner M et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007; 119:982-90.
147. Soumelis V, Reche PA, Kanzler H et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3:673-80.
148. He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS. TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Nat Acad Sci 2008; 105:11875-80.
149. Semlali A, Jacques E, Koussih L, Gounni AS, Chakir J. Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J Allergy Clin Immunol 2010; 125:844-50.
150. Shikotra A, Choy DF, Ohri CM et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012; 129:104-11, e101-9.
151. Lee KH, Cho KA, Kim JY, Baek JH, Woo SY, Kim JW. Filaggrin knockdown and Toll-like receptor 3 (TLR3) stimulation enhanced the production of thymic stromal lymphopoietin (TSLP) from epidermal layers. Exp Dermatol 2011; 20:149-51.
152. Pushparaj PN, Tay HK, H'ng SC et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Nat Acad Sci 2009; 106:9773-8.
153. Ahdieh M, Vandenbos T, Youakim A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am J Physiol Cell Physiol 2001; 281:C2029-38.
154. Colgan SP, Resnick MB, Parkos CA et al. IL-4 directly modulates function of a model human intestinal epithelium. J Immunol 1994; 153:2122-9.
155. Ceponis PJ, Botelho F, Richards CD, McKay DM. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem 2000; 275:29132-7.
156. Prasad S, Mingrino R, Kaukinen K et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005; 85:1139-62.
157. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129:550-64.
158. Madden KB, Whitman L, Sullivan C et al. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol 2002; 169:4417-22.
159. Salmon-Ehr V, Ramont L, Godeau G et al. Implication of Interleukin-4 in Wound Healing. Lab Invest 2000; 80:1337-43.
160. Kim I, Mogford JE, Chao JD, Mustoe TA. Wound epithelialization deficits in the transforming growth factor-alpha knockout mouse. Wound Repair Regen 2001; 9:386-90.
161. Brown RL, Ormsby I, Doetschman TC, Greenhalgh DG. Wound healing in the transforming growth factor-beta-deficient mouse. Wound Repair Regen 1995; 3:25-36.
162. Laato M, Heino J, Gerdin B, Kahari VM, Niinikoski J. Interferon-gamma-induced inhibition of wound healing in vivo and in vitro. Ann Chir Gynaecol 2001; 90(Suppl 215):19-23.
163. Miles RH, Paxton TP, Zacheis D, Dries DJ, Gamelli RL. Systemic administration of interferon-gamma impairs wound healing. J Surg Res 1994; 56:288-94.
164. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol 1993; 74:79-85.
165. Torma H, Lindberg M, Berne B. Skin barrier disruption by sodium lauryl sulfate-exposure alters the expressions of involucrin, transglutaminase 1, profilaggrin, and kallikreins during the repair phase in human skin in vivo. J Invest Dermatol 2007; 128:1212-9.